Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

1.21USD
4:00pm EDT
Change (% chg)

$-0.07 (-5.47%)
Prev Close
$1.28
Open
$1.27
Day's High
$1.28
Day's Low
$1.17
Volume
221,220
Avg. Vol
111,501
52-wk High
$3.49
52-wk Low
$1.17

ECYT.OQ

Chart for ECYT.OQ

About

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $54.50
Shares Outstanding(Mil.): 42.58
Dividend: --
Yield (%): --

Financials

  ECYT.OQ Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -1.01 -- --
ROI: -31.67 2.87 14.88
ROE: -31.86 5.20 16.12

BRIEF-Endocyte Q2 loss per share $0.28

* Endocyte reports second quarter financial results and provides clinical and pipeline update

Aug 08 2017

BRIEF-Endocyte form 4 discloses CEO's 44,285 stock options fully vested on May 31, immediately exercisable

* Endocyte Inc form 4 discloses that CEO Michael Sherman's 44,285 stock options (right to buy) fully vested on may 31 and immediately exercisable - sec filing Source text (http://bit.ly/2rytsCJ) Further company coverage:

Jun 02 2017

BRIEF-Endocyte announces clinical updates for EC1456 and EC1169

* Endocyte Inc - continuing EC1169 program in taxane-exposed patients, but ending clinical development of EC1456 and of EC1169 in taxane-naïve patients

Jun 02 2017

BRIEF-Endocyte Q1 loss per share $0.27

* Endocyte reports first quarter financial results and provides clinical and pipeline update

May 10 2017

BRIEF-Endocyte Inc presents data at AACR identifying multiple methods for managing severe side effects resulting from car t-cell treatment

* Endocyte Inc - presents data at AACR identifying multiple methods for managing severe side effects resulting from car t-cell treatment

Apr 05 2017

BRIEF-Endocyte plans to collaborate with Seattle Children's Research Institute

* Endocyte Inc - plan to collaborate with seattle children's research institute and Dr. Michael Jensen for development of Endocyte's SMDC platform Source text for Eikon: Further company coverage:

Mar 10 2017

BRIEF-Endocyte Q4 loss per share $0.26

* Endocyte reports fourth quarter and year end 2016 financial results and provides clinical and pipeline update

Mar 10 2017

BRIEF-Endocyte appoints Michael T. Andriole as CFO

* Endocyte appoints Michael T. Andriole as chief financial officer Source text for Eikon: Further company coverage:

Feb 21 2017

Competitors

Earnings vs. Estimates